var title_f0_56_896="Trans-urethral bladder catheterization boys";
var content_f0_56_896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proper position for penis in transurethral bladder catheterization in males",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The urethra is straightened by using the nondominant hand to hold the penis perpendicular to the lower abdomen. Gentle traction is applied. The catheter is inserted with the dominant hand until urine returns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_896=[""].join("\n");
var outline_f0_56_896=null;
var title_f0_56_897="TTTS4";
var content_f0_56_897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Donor twin with marked oligohydramnios at 24 2/7 weeks of gestation. Arrow denotes the membrane which can be seen extending between the lower fetal abdomen and the fetal thigh. The difficulty is finding this membrane can often lead to the erroneous diagnosis of monoamniotic twins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_897=[""].join("\n");
var outline_f0_56_897=null;
var title_f0_56_898="Ht age boys z 2 5";
var content_f0_56_898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Height-for-age boys: 2 to 5 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_898=[""].join("\n");
var outline_f0_56_898=null;
var title_f0_56_899="4 chamber view LV mass";
var content_f0_56_899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determination of left ventricular myocardial mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Orthogonal apical echocardiographic&nbsp;views are digitized in systole and diastole and the computer analyzes the tracings according to two volume algorithms and, using the truncate ellipsoid method, computes the internal dimensions used in the calculation of mass. By this method the ejection fraction is borderline normal at 55 percent and the mass is increased at 220 g; assuming a body surface area of 2 msq, the mass is 110 g/msq, well over two standard deviations from the mean of 95 g/msq. The end systolic volume index is 33 ml/msq and also exceeds the bounds for normality. By comparing the diastolic to the systolic area tracings it can be seen that the descent of the base is less than 14 mm. Since increased left ventricular mass imparts a lower wall stress and afterload, the borderline ejection fraction becomes clearly abnormal (unless blood pressure is greatly elevated).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_899=[""].join("\n");
var outline_f0_56_899=null;
var title_f0_56_900="Oxacillin: Patient drug information";
var content_f0_56_900=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxacillin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     see \"Oxacillin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"     see \"Oxacillin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxacillin, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11817 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_900=[""].join("\n");
var outline_f0_56_900=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015585\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015584\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015589\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015590\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015592\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015587\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015588\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015593\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015594\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=related_link\">",
"      Oxacillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=related_link\">",
"      Oxacillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_901="Zidovudine and lamivudine: Drug information";
var content_f0_56_901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zidovudine and lamivudine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/1/32789?source=see_link\">",
"    see \"Zidovudine and lamivudine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/61/19413?source=see_link\">",
"    see \"Zidovudine and lamivudine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combivir&reg;;",
"     </li>",
"     <li>",
"      Teva-Lamivudine/Zidovudine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral: 1 tablet twice daily. Because this is a fixed-dose combination product, avoid use in patients requiring dosage reduction including children &lt;30 kg, renally-impaired patients with a creatinine clearance &lt;50 mL/minute, hepatic impairment, or those patients experiencing dose-limiting adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F235249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/61/19413?source=see_link\">",
"      see \"Zidovudine and lamivudine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents &ge;30 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/min: Fixed-dose combination lamivudine/zidovudine is not recommended;  use individual components for patients requiring dose adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fixed-dose combination lamivudine/zidovudine is not recommended; use individual components for patients requiring dose adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: Lamivudine 150 mg and zidovudine 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combivir&reg;: Lamivudine 150 mg and zidovudine 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F235261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Combivir&reg; may be confused with Combivent&reg;, Epivir&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AZT is an error-prone abbreviation (mistaken as azaTHIOprine, aztreonam)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3945445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lamivudine, zidovudine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3945446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Zidovudine is associated with hematologic toxicity including neutropenia and severe anemia.",
"     </b>",
"     Use with caution in patients with bone marrow compromise (granulocytes &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or hemoglobin &lt;9.5 mg/dL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy:",
"     <b>",
"      [U.S. Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy and myositis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Monitor closely for chronic hepatitis B for several months following discontinuation of therapy",
"     </b>",
"     in patients coinfected with HBV and HIV; clinical exacerbations may occur and may warrant antihepatitis B therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combivir&reg; is not recommended for use in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Combivir&reg; is not recommended for use in patients with renal (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Concomitant use of other zidovudine- or lamivudine-containing products should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Emtricitabine: Concomitant use of emtricitabine-containing products should be avoided; cross-resistance may develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HBV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F235235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F235233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Combivir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-300 mg (60): $1081.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lamivudine-Zidovudine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-300 mg (60): $931.61",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3945453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amylase, bilirubin, signs and symptoms of pancreatitis. Monitor CBC with differential and platelet count at least every 2 weeks, liver function tests (including signs/symptoms of hepatomegaly), MCV, serum creatinine kinase, viral load, and CD4 count; observe for appearance of opportunistic infections; signs of muscle weakness or pain; blood lactate levels and signs of acidosis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F235236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biovir (BR);",
"     </li>",
"     <li>",
"      Cipladuovir (CO);",
"     </li>",
"     <li>",
"      Combivir (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, IE, IL, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, SY, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Duovir (IN);",
"     </li>",
"     <li>",
"      Ganvirel Duo (AR);",
"     </li>",
"     <li>",
"      Lamuzid (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Virdual (CO);",
"     </li>",
"     <li>",
"      Zovilam (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F235219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The combination of zidovudine and lamivudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10221 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_901=[""].join("\n");
var outline_f0_56_901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708844\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235256\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235243\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235249\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160259\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160260\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235227\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235216\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235229\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235261\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235254\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3945445\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3945446\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235250\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235224\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235234\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235246\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235235\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235233\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3945453\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235236\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235219\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10221|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/1/32789?source=related_link\">",
"      Zidovudine and lamivudine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/61/19413?source=related_link\">",
"      Zidovudine and lamivudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_902="Atovaquone and proguanil: Drug information";
var content_f0_56_902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atovaquone and proguanil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/10/41124?source=see_link\">",
"    see \"Atovaquone and proguanil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19365?source=see_link\">",
"    see \"Atovaquone and proguanil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;;",
"     </li>",
"     <li>",
"      Malarone&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of malaria:",
"     </b>",
"     Oral: Atovaquone/proguanil 250 mg/100 mg once daily; start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute malaria:",
"     </b>",
"     Oral: Atovaquone/proguanil 1 g/400 mg as a single dose, once daily for 3 consecutive days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19365?source=see_link\">",
"      see \"Atovaquone and proguanil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of malaria:",
"     </b>",
"     Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning. Take as a single dose, once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-8 kg (unlabeled dosing): Atovaquone/proguanil 31.25 mg/12.5 mg (Boggild,  2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-10 kg (unlabeled dosing): Atovaquone/proguanil 46.8 mg/18.75 mg (Boggild,  2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11-20 kg: Atovaquone/proguanil 62.5 mg/25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21-30 kg: Atovaquone/proguanil 125 mg/50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31-40 kg: Atovaquone/proguanil 187.5 mg/75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: Atovaquone/proguanil 250 mg/100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute malaria:",
"     </b>",
"     Oral: Take as a single dose, once daily for 3 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-8 kg: Atovaquone/proguanil 125 mg/50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-10 kg: Atovaquone/proguanil 187.5 mg/75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11-20 kg: Atovaquone/proguanil 250 mg/100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21-30 kg: Atovaquone/proguanil 500 mg/200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31-40 kg: Atovaquone/proguanil 750 mg/300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: Atovaquone/proguanil 1 g/400 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution due to possible decrease in renal and hepatic function, as well as possible decreases in cardiac function, concomitant diseases, or other drug therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required in mild-to-moderate renal impairment. Contraindicated as prophylaxis in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). May use for 3-day treatment in patients with severe renal impairment if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required in mild-to-moderate hepatic impairment. No data available for use in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Atovaquone 250 mg and proguanil hydrochloride 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malarone&reg;: Atovaquone 250 mg and proguanil hydrochloride 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malarone&reg;: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes pediatric strength tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or milk-based drink at the same time each day. If vomiting occurs within 1 hour of administration, repeat the dose. For children who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention or treatment of acute, uncomplicated",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following adverse reactions were reported in patients being treated for malaria. When used for prophylaxis, reactions are similar to those seen with placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (17%), nausea (12%), vomiting (children 10% to 13%, adults 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminase increases (ALT 27%,  AST 17%; increased LFT values typically normalized after ~4 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (10%), dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (children 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (children 6%, adults 8%), anorexia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis (rare), anemia (rare), angioedema, cholestasis, erythema multiforme (rare), hallucinations, hepatitis (rare), hepatic failure (case report), neutropenia, pancytopenia (with severe renal impairment), photosensitivity, psychotic episodes (rare), rash, seizure (rare), Stevens-Johnson syndrome (rare), stomatitis, urticaria, vasculitis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atovaquone, proguanil, or any component of the formulation; prophylactic use in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Increased transaminase levels and hepatitis (rare) have been reported with prophylactic use; single case report of hepatic failure requiring transplantation documented. Monitor closely and use caution in patients with existing hepatic impairment. Data from clinical trials indicates that elevations in AST/ALT may persist for up to 4 weeks following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea/vomiting: Absorption of atovaquone may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antimalarial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malaria: Appropriate use: Not indicated for severe or complicated malaria. Delayed cases of",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria may occur after stopping prophylaxis; travelers returning from endemic areas who develop febrile illnesses should be evaluated for malaria. Recrudescent infections or infections following prophylaxis with this agent should be treated with alternative agent(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal disease. May use with caution for treatment  of malaria in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) if benefit outweighs risk. Contraindicated for prophylactic use in severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Treatment failures have been reported in patients &gt;100 kg (case reports); follow-up monitoring is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use in patients &lt;5 kg.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Separate administration of atovaquone and etoposide by at least 1-2 days. Avoid concomitant administration of atovaquone and etoposide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Atovaquone may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F137591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Atovaquone taken with dietary fat significantly increases the rate and extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of atovaquone. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed with the combination of atovaquone/proguanil in animal reproduction studies using concentrations similar to the estimated human exposure. The pharmacokinetics of atovaquone and proguanil are changed during pregnancy. Malaria infection in pregnant women may be more severe than in nonpregnant women. Because",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Atovaquone/proguanil may be used as an alternative treatment of malaria in pregnant women; consult current CDC guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atovaquone: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proguanil: Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9760124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small quantities of proguanil are found in breast milk. This combination is not recommended if nursing infants &lt;5 kg (safety data is limited concerning therapeutic use in infants &lt;5 kg)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken with food or milk-based drink.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atovaquone-Proguanil HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     62.5-25 mg (100): $264.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-100 mg (100): $714.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Malarone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     62.5-25 mg (100): $298.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-100 mg (24): $197.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9760127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver and renal function; closely monitor response to treatment in patients &gt;100 kg",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Malalone (KP);",
"     </li>",
"     <li>",
"      Malanil (TH);",
"     </li>",
"     <li>",
"      Malarone (AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, MY, NL, NO, PE, PL, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atovaquone: Selectively inhibits parasite mitochondrial electron transport.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proguanil: The metabolite cycloguanil inhibits dihydrofolate reductase, disrupting deoxythymidylate synthesis. Together, atovaquone/cycloguanil affect the erythrocytic and exoerythrocytic stages of development.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atovaquone:",
"     </b>",
"     See Atovaquone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Proguanil:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :  Adults and Children &gt;15 years of age and 31-110 kg: 1617-2502 L; Pediatric patients &le;15 years and 11-56 kg: 62-966 L; concentrated in erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolites, cycloguanil (via CYP2C19) and 4-chlorophenylbiguanide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bioavailability: &le;60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 12-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (40% to 60%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boggild AK, Parise ME, Lewis LS, et al, &ldquo;Atovaquone-Proguanil: Report From The CDC Expert Meeting On Malaria Chemoprophylaxis  (II),&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2007, 76(2):208-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/902/abstract-text/17297027/pubmed\" id=\"17297027\" target=\"_blank\">",
"        17297027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand R, Prendki V, Cailhol J, et al, &ldquo;",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Malaria and Atovaquone-Proguanil Treatment Failure,&rdquo;",
"      <i>",
"       Emerg Infect Dis",
"      </i>",
"      , 2008, 14(2):320-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/902/abstract-text/18258131/pubmed\" id=\"18258131\" target=\"_blank\">",
"        18258131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8704 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_902=[""].join("\n");
var outline_f0_56_902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137595\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137596\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137614\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137598\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137608\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137599\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137600\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137601\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137574\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137560\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137577\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137575\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137612\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137580\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137564\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137609\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137569\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137591\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137582\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137604\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9760124\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137583\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137581\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9760127\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137584\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137563\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137579\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/10/41124?source=related_link\">",
"      Atovaquone and proguanil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19365?source=related_link\">",
"      Atovaquone and proguanil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_903="Isradipine: Drug information";
var content_f0_56_903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isradipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/4/26692?source=see_link\">",
"    see \"Isradipine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"    see \"Isradipine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10095388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DynaCirc CR&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 2.5 mg twice daily; antihypertensive response occurs in 2-3 hours; maximal response in 2-4 weeks; increase dose at 2- to 4-week intervals at 2.5-5 mg increments; usual dose range (JNC 7): 2.5-10 mg/day in 2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Most patients show no improvement with doses &gt;10 mg/day except adverse reaction rate increases; therefore, maximal dose in older adults should be 10 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled release tablet: 5 mg once daily; antihypertensive response occurs in 2 hours. Adjust dose in increments of 5 mg at 2-4 week intervals. Maximum dose: 20 mg/day; adverse events are increased at doses &gt;10 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4476167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"      see \"Isradipine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Hypertension (unlabeled use): Capsule: Oral: Initial: 0.15-0.2 mg/kg/day in 2-3 divided doses; maximum 0.8 mg/kg/day, up to 20 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Controlled release formulation is administered once daily or in 2 divided doses.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled release tablet: Initial dose: 5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3031496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Bioavailability increased by 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute on hemodialysis: Bioavailability decreased by 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Capsule: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled release tablet: Initial dose: 5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3031497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peak serum concentrations are increased by 32% and bioavailability is increased by 52%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Capsule: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled release tablet: Initial dose: 5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DynaCirc CR&reg;: 5 mg [DSC], 10 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Controlled release tablets should be swallowed whole; do not divide or chew",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4589528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DynaCirc&reg; may be confused with Dynacin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Percentages reported with capsule formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (dose related 2% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (dose related 1% to 9%), palpitation (dose related 1% to 5%), flushing (dose related 1% to 5%), tachycardia (1% to 3%), chest pain (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 8%), fatigue (dose related 1% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 5%), abdominal discomfort (&le;3%), vomiting (&le;1%), diarrhea (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urinary frequency (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, atrial fibrillation, back pain, constipation, cough, cramps of legs and feet, depression, drowsiness, drug fever, dry mouth, dysuria, epistaxis, gingival hyperplasia (incidence unknown), heart failure, hyperhidrosis, hypotension, impotence, insomnia, joint pain, leg pain, lethargy, leukopenia, libido decreased, liver function tests increased, MI, nasal congestion, nervousness, nocturia, numbness, paresthesia, pruritus, stroke, syncope, throat discomfort, transient ischemic attack, urticaria, ventricular fibrillation, visual disturbance, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isradipine or any component of the formulation; hypotension (&lt;90 mm Hg systolic)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Idiopathic hypertrophic subaortic stenosis (IHSS): Use with caution in patients with IHSS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Controlled release tablets: Use controlled release tablets with caution in patients with severe GI narrowing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Titration: Adjust doses at 2- to 4-week intervals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F185325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Administration with food delays absorption, but does not affect availability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease isradipine levels; dong quai has estrogenic effects. Some herbal medications may worsen hypertension (eg, licorice); garlic may have additional antihypertensive effects. Management: Avoid dong quai and St John's wort. Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), gotu kola, licorice, yohimbe, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Israpidine crosses the human placenta. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F185337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F185315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F185313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Isradipine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $136.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $199.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3031498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; renal, hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      DynaCirc (AR);",
"     </li>",
"     <li>",
"      Dynacirc (BB, BM, BS, BZ, CO, GY, HK, JM, MX, MY, PH, PK, SR, TH, TR, TT, TW, VE);",
"     </li>",
"     <li>",
"      Dynacirc SR (KP);",
"     </li>",
"     <li>",
"      Dynacirc SRO (CN, CO, MX, MY, NZ, SG, TH);",
"     </li>",
"     <li>",
"      Icaz LP (FR);",
"     </li>",
"     <li>",
"      Icaz SRO (PH);",
"     </li>",
"     <li>",
"      Lomir (AE, AT, BE, BF, BH, BJ, BR, CH, CI, CY, CZ, DE, EG, ES, ET, FI, GH, GM, GN, GR, HN, HU, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, PL, PT, QA, RU, SA, SC, SD, SE, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lomir Retard (DK);",
"     </li>",
"     <li>",
"      Lomir SRO (AT, CH, CZ, FI, HN, IT, NL, NO, PL, PT, SE);",
"     </li>",
"     <li>",
"      Prescal (GB);",
"     </li>",
"     <li>",
"      Tenzipin (HR);",
"     </li>",
"     <li>",
"      Vascal (DE);",
"     </li>",
"     <li>",
"      Vaslan (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: &gt;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 90% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect; forms metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 15% to 24%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 65% as metabolites); feces (25% to 30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2000, 36(3):970-1062.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/903/abstract-text/10987629/pubmed\" id=\"10987629\" target=\"_blank\">",
"        10987629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/903/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/903/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lunell NO, Bondesson U, Grunewald C, et al, &ldquo;Transplacental Passage of Isradipine in the Treatment of Pregnancy-Induced Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1993, 6(3 Pt 2):110-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/903/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/56/903/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8585 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_903=[""].join("\n");
var outline_f0_56_903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185369\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185333\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476167\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185334\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3031496\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3031497\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185303\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185290\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185307\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185306\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589528\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185376\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185367\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185311\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185294\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185363\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185299\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185325\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185300\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185314\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185337\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185315\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185313\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3031498\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185316\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185293\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185310\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8585|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/4/26692?source=related_link\">",
"      Isradipine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=related_link\">",
"      Isradipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_904="Clear cell carc MRI A";
var content_f0_56_904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73120%7EONC%2F51129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73120%7EONC%2F51129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance images (MRI) of clear cell carcinoma of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T2-weighted single-shot fast spin echo image shows a heterogeneous mass in the right kidney.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ivan Pedrosa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance images (MRI) of clear cell carcinoma of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal three-dimensional T1-weighted fat-saturated gradient echo image after administration of gadolinium obtained during the excretory phase confirms the presence of enhancement (compared to pre-contrast, not shown) within the mass. After nephrectomy, a low grade (Furhman nuclear grade 2) clear-cell renal cell carcinoma was confirmed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_904=[""].join("\n");
var outline_f0_56_904=null;
var title_f0_56_905="Approach to the metabolic myopathies";
var content_f0_56_905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the metabolic myopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/905/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/905/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/905/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/56/905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will provide an overview of the evaluation of the patient with a suspected metabolic myopathy. Detailed descriptions of the different disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the biochemistry of energy metabolism in muscle is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link\">",
"     \"Energy metabolism in muscle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms, signs, and laboratory abnormalities resulting from a metabolic myopathy vary with the underlying defect. The diagnosis of these disorders depends upon a constellation of findings, including the type of muscle involvement, specific laboratory abnormalities (particularly elevations in serum creatine kinase and myoglobinuria), patient age, family history, and the results of histologic and pathologic examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Disorders of glycogen metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited disorders that result in abnormal storage of glycogen are known as glycogen storage diseases. These disorders have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from birth to adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with defects of carbohydrate metabolism, muscle symptoms are induced by either brief isometric exercise, such as lifting heavy weights, or by less intense but sustained dynamic exercise, such as swimming, climbing stairs, or running. Acute muscle breakdown may lead to myoglobinuria, cramps, and muscle swelling.",
"   </p>",
"   <p>",
"    In young children, defects in glycogenolysis may present with liver dysfunction, hepatomegaly, failure to thrive, hypoglycemia (sometimes with associated hypoglycemic seizures), gross motor delay, peripheral neuropathy, cardiac involvement, hemolytic anemia with jaundice, splenomegaly, and myoglobinuria. Mental retardation, upper and lower motor neuron involvement with sensory loss, sphincter problems, and neurogenic bladder may also be observed.",
"   </p>",
"   <p>",
"    The principal symptoms and signs, however, are those related to exercise intolerance and recurrent myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with defects of glycogen metabolism usually complain of easy fatigability upon exertion and, occasionally, of muscle stiffness induced by exercise. In some cases, brief rest when muscle symptoms develop can subsequently result in improved exercise tolerance, referred to as the spontaneous \"second wind\" [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/3\">",
"     3",
"    </a>",
"    ]. \"Second wind\" also can be induced by the infusion of carbohydrate fuel (eg, glucose) or lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with certain glycolytic defects (eg, muscle phosphofructokinase deficiency), however, are unable to achieve a spontaneous second wind [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/5\">",
"     5",
"    </a>",
"    ] or have worsening of symptoms after the administration of glucose (the \"out of wind\" phenomenon\") [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=see_link\">",
"     \"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disorders of lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic myopathies resulting from disorders of lipid metabolism include the following conditions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Defects of beta-oxidation enzymes",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency syndromes",
"     </li>",
"     <li>",
"      Fatty acid transport defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With disorders of lipid metabolism, symptoms are usually induced by prolonged exercise and prolonged fasting. These patients, in contrast to those with glycogen metabolism defects, do not develop true muscle cramps or contractures, and do not experience a \"second wind.\" Their symptoms and signs, such as muscle pain, tightness, or myoglobinuria, are usually induced by infection, general anesthesia, exposure to cold, and a low-carbohydrate, high-fat diet [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have suggested that there are four main clinical and laboratory features that should lead the clinician to suspect a fatty acid oxidation disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Involvement of fatty acid oxidation-dependent tissues, such as the heart, muscle, and liver",
"     </li>",
"     <li>",
"      Recurrent episodes of hypoketotic hypoglycemia (ketoacidosis does not occur because fatty acids cannot be converted to ketoacids in the liver)",
"     </li>",
"     <li>",
"      Acute metabolic decompensation in association with fasting",
"     </li>",
"     <li>",
"      Alterations in plasma and tissue concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skeletal muscle, heart, and liver are highly dependent upon efficient fatty acid utilization. Fatty acids are a major source of energy for the heart and liver, particularly during fasting when glycogen and glucose stores have been depleted. In addition, resting muscle and exercising muscle during mild to moderate prolonged exercise derive most of the required energy from fatty acid oxidation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link\">",
"     \"Energy metabolism in muscle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among fasting patients with fatty acid oxidation defects, the free fatty acids cannot be metabolized because of the existing metabolic block; as a result, they are stored in the cytoplasm as triglycerides, thereby resulting in progressive lipid storage myopathy with weakness, hypertrophic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dilated cardiomyopathy, and fatty liver. In addition, with fasting, glucose and glycogen stores are depleted and ketone bodies are not generated because of the existing metabolic block. As a result, the ratio of serum free fatty acids to ketones increases from the normal ratio of 1:1 to more than 2:1, which is highly suggestive of a block in beta-oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other conditions that can lead to metabolic decompensation among patients with fatty acid oxidation defects include cold-induced shivering thermogenesis and infection with vomiting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With cold exposure, shivering depends heavily upon long-chain fatty acid oxidation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      After prolonged fasting or during infections, children can become comatose and present with symptoms similar to Reye syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    levels vary with the various defects of lipid metabolism. With carnitine transport defects, for example, total serum carnitine is significantly reduced (eg, less than 5 percent of normal) and the esterified fraction is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/9\">",
"     9",
"    </a>",
"    ]. This finding is probably related to both reduced renal carnitine reabsorption, leading to carnitine leak, and defective intestinal carnitine absorption.",
"   </p>",
"   <p>",
"    By comparison, in the majority of cases of intramitochondrial beta-oxidation defects, the amount of total serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is reduced to less than 50 percent of normal, and the esterified carnitine fraction is increased to more than 50 percent of normal (normal: 10 to 25 percent in the fed state and 30 to 50 percent during fasting) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/8\">",
"     8",
"    </a>",
"    ]. This occurs because the accumulating longer-chain-length acylcarnitines are reabsorbed much more easily at the renal tubular reabsorptive site than free carnitine. As a result, the free carnitine fraction will be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Lipid metabolism defects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H400795808\">",
"    <span class=\"h2\">",
"     Mitochondrial disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise intolerance due to premature fatigue is a common manifestation of mitochondrial diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the exercise intolerance is usually more severe than muscle weakness. In contrast to those with glycogen metabolism defects, patients with isolated mitochondrial myopathy do not develop true muscle cramps or a \"second wind.\" Resting venous lactic acidosis is common in such patients, who are sometimes misdiagnosed as having chronic fatigue syndrome or fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link&amp;anchor=H5#H5\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'Isolated myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myoglobinuria and rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic myopathies, such as those with inherited disorders of glycogenolysis, glycolysis, lipid metabolism, or purine metabolism (",
"    <a class=\"graphic graphic_table graphicRef61324 \" href=\"UTD.htm?24/58/25515\">",
"     table 2",
"    </a>",
"    ), may be at increased risk for developing myoglobinuria and rhabdomyolysis. The manifestations and complications of rhabdomyolysis result from muscle cell death, with the release of intracellular muscle constituents into the circulation.",
"   </p>",
"   <p>",
"    The clinical features of rhabdomyolysis include myalgias, weakness, and elevated serum muscle enzymes (including creatine kinase). Acute muscle breakdown of sufficient severity can lead to myoglobinemia and myoglobinuria. The urine acquires a brownish, cola-like color, and the supernatant is positive for heme in the absence of red blood cells in the sediment. The degree of myalgias and other symptoms varies widely, and some patients are asymptomatic. Fever, malaise, tachycardia, and gastrointestinal symptoms may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link&amp;anchor=H25330957#H25330957\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other manifestations include fluid and electrolyte abnormalities, many of which precede, or occur in the absence of, acute kidney injury and hepatic injury. Hypovolemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, and metabolic acidoses can develop. Hyperkalemia may result in cardiac dysrhythmias. Later complications include acute kidney injury, hypercalcemia, compartment syndrome, and, rarely, disseminated intravascular coagulation.",
"   </p>",
"   <p>",
"    The metabolic myopathies represent a small percentage of all cases of rhabdomyolysis but are relatively common causes among patients with recurrent episodes of rhabdomyolysis after exertion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 475 hospitalized adults with rhabdomyolysis, the most frequent etiology was an exogenous toxin (46 percent), a category that included alcohol, illicit drugs, and prescribed drugs (eg, antipsychotics, statins,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , selective serotonin reuptake inhibitors and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/11\">",
"       11",
"      </a>",
"      ]. Less common causes included trauma, seizures, immobility, critical illness myopathy, exercise,",
"      <span class=\"nowrap\">",
"       heat/dehydration,",
"      </span>",
"      and hypothermia. Multiple factors could be identified in 60 percent of cases. An underlying myopathy or metabolic muscle defect was diagnosed in only 10 percent of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/11\">",
"       11",
"      </a>",
"      ]. In this group, recurrences were common, the incidence of acute renal failure was low, and typically only one etiologic factor could be identified. Myoglobinuria was detected by",
"      <span class=\"nowrap\">",
"       dipstick/ultrafiltration",
"      </span>",
"      in 19 percent of the patients.",
"     </li>",
"     <li>",
"      In a series of 191 children treated in the emergency department of a pediatric tertiary care hospital, the most common causes of rhabdomyolysis were viral myositis, trauma, and connective tissue diseases, found in 38, 26, and 5 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/12\">",
"       12",
"      </a>",
"      ]. Among children with CK values &ge;6000",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      a genetically determined metabolic myopathy or undiagnosed dermatomyositis was present in 6 of 37 (16 percent), while in children with CK levels of 1000 to 5999",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      the proportion was 10 of 154 (6 percent). The incidence of acute renal failure in children in this study (5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/12\">",
"       12",
"      </a>",
"      ] was much lower than that reported in the adult series (46 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/11\">",
"       11",
"      </a>",
"      ] discussed above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although exercise intolerance, often dating back to childhood, is common in patients with mitochondrial defects, rhabdomyolysis with resultant myoglobinuria is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/13\">",
"     13",
"    </a>",
"    ]. However, myoglobinuria has been reported in patients with mutations involving cytochrome b, cytochrome c oxidase (cox), and the MELAS A3260G mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of myoglobinuria due to a metabolic defect may vary among children and adults. In a large series of children with recurrent myoglobinuria, an enzyme abnormality could be detected in only 24 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/17\">",
"     17",
"    </a>",
"    ]; by comparison, a similar adult series of 77 patients found a biochemical abnormality in 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/18\">",
"     18",
"    </a>",
"    ]. The most common metabolic cause of recurrent myoglobinuria in both adults and children is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    palmitoyltransferase II deficiency. Myoglobinuria may also occur in patients with dystrophinopathies or caveolinopathies (ie, limb-girdle muscular dystrophy type 1C) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to myoglobinuria and rhabdomyolysis is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    ). Briefly, the laboratory findings that characterize rhabdomyolysis include an acute elevation in the creatine kinase &ndash; typically at least five times the upper limit of normal at presentation &ndash; and other muscle enzymes, followed by a decline in these values three to five days after cessation of muscle injury. The other characteristic finding is the reddish-brown urine of myoglobinuria, but this finding is often absent because of the relative rapidity with which myoglobin is cleared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H400795568\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general approach to the diagnosis of metabolic myopathies is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef71018 \" href=\"UTD.htm?18/38/19044\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients with a metabolic myopathy (eg, glycogen storage diseases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    palmitoyltransferase deficiency) have dynamic rather than static symptoms, and therefore usually complain of exercise intolerance, muscle pain and cramps rather than fixed weakness with exercise. Nevertheless, some patients may develop progressive muscular weakness that is usually proximal, mimicking inflammatory myopathy or limb girdle muscular dystrophy, but is sometimes distal. In a smaller group of patients, both dynamic and static symptoms predominate (",
"    <a class=\"graphic graphic_table graphicRef59733 \" href=\"UTD.htm?8/50/9004\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The laboratory investigation of patients with suspected metabolic myopathies includes serum and urine testing, the forearm ischemic exercise test, electromyography, muscle biopsy, and, in some cases, nuclear magnetic resonance spectroscopy, if available (",
"    <a class=\"graphic graphic_table graphicRef56365 \" href=\"UTD.htm?10/4/10317\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other etiologies (eg, toxic, traumatic, alcohol- and drug-related, endocrine, viral and inflammatory) should be considered and appropriate testing should be performed to exclude them prior to investigating a metabolic etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptom assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When confronted with a patient with a possible metabolic myopathy, the first step is to determine whether the symptoms are dynamic, static, or both (",
"    <a class=\"graphic graphic_table graphicRef59733 \" href=\"UTD.htm?8/50/9004\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with dynamic symptoms develop acute and recurrent episodes of irreversible muscle dysfunction related to exercise intolerance, prolonged fasting, exposure to cold, general anesthesia, intercurrent infection, or low-carbohydrate, high-fat diet. Some of these patients may develop myoglobinuria. In between episodes, the patients are free of symptoms.",
"     </li>",
"     <li>",
"      Static symptoms include proximal weakness (which is indistinguishable from limb-girdle muscular dystrophies), occasionally distal weakness, generalized muscle weakness, and respiratory difficulties related to involvement of respiratory muscles or fixed cardiomyopathy (as in acid maltase deficiency). Other static features include progressive external ophthalmoplegia, peripheral neuropathies, seizures, developmental delay, failure to thrive, short stature, deafness, and ataxia. The symptoms themselves are not necessarily static since progression of varying degree usually occurs depending upon the severity and type of defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both dynamic and static symptoms are common in mitochondrial myopathies related to either mitochondrial DNA defects or specific inborn errors of fatty acid oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second step is targeted at determining the type of the underlying biochemical abnormality as suggested by the pattern of symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef71018 \" href=\"UTD.htm?18/38/19044\">",
"     algorithm 1",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who develop symptoms after prolonged, mild to moderate, low-intensity activity (such as walking) may have a defect in fatty acid oxidation (especially if the symptoms occur after one hour).",
"     </li>",
"     <li>",
"      Symptoms developing during or after high-intensity isometric exercise (such as pushing a stalled car or lifting weights) or high-intensity, sustained, submaximal exercise (such as sprinting) suggest a defect in glycogen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucose metabolism; these symptoms tend to occur early, typically within 10 minutes of activity onset [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects in glucose, glycogen, or fatty acid metabolism may be observed among patients with symptoms produced by low-intensity, submaximal exercise (eg, running slowly).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Table provides a list of the various biochemical defects, categorized on the basis of the symptoms they produce (",
"    <a class=\"graphic graphic_table graphicRef59733 \" href=\"UTD.htm?8/50/9004\">",
"     table 3",
"    </a>",
"    ). The general approach to the patient with and the differential diagnosis of muscle weakness is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serum and urine testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal levels of specific compounds in the blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine, either alone or in combination, may help diagnose or suggest a specific metabolic abnormality. These include serum levels of lactate, pyruvate, lactic acid dehydrogenase, uric acid, free and total",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , ketones, glucose, ammonia, myoglobin, liver transaminases, potassium, calcium, phosphate, creatinine, and acylcarnitine, and urinary levels of ketones, myoglobin, dicarboxylic acids, and acylglycines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary myoglobin excretion, which should be measured at rest and with exercise, can be induced by inborn errors of",
"      <span class=\"nowrap\">",
"       glycogen/glucose",
"      </span>",
"      metabolism, fatty acid metabolism, and some mitochondrial DNA defects. The induction of myoglobinuria by pure exertion or by toxic factors, such as infection and fever, may suggest a particular disorder. As an example, a clinical presentation with features of a Reye-like syndrome or with myoglobinuria induced by toxic factors suggests a fatty acid oxidation defect [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with acute myoglobinuria may have concurrent elevations of serum creatinine, potassium, phosphate, uric acid, and even amino acids (particularly taurine). The serum calcium is usually low, but hypercalcemia may develop after recovery from renal failure.",
"     </li>",
"     <li>",
"      The serum creatine kinase concentration should be tested at rest and during episodes of acute recurrent muscle dysfunction, with or without myoglobinuria. In patients with glycogen defects, the creatine kinase level may be elevated at rest, particularly in patients with static symptoms. By comparison, the creatine kinase level in patients with CPT II deficiency may be normal between acute episodes.",
"     </li>",
"     <li>",
"      Dicarboxylic acids are detected in the urine of all patients with intramitochondrial beta-oxidation defects and respiratory chain enzyme defects (due to secondary inhibition of fatty acid oxidation) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/21\">",
"       21",
"      </a>",
"      ]. This change is not seen with defects involving the transport of long-chain fatty acids into the mitochondria and also in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      uptake defects. Dicarboxylic aciduria can also result from a medium chain triglyceride enriched diet as used for premature infants and for patients with cholestatic hepatopathy.",
"     </li>",
"     <li>",
"      Serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine levels of lactate and pyruvate may be elevated in patients with mitochondrial myopathies. The",
"      <span class=\"nowrap\">",
"       lactate/pyruvate",
"      </span>",
"      ratio (normally &lt;20) in blood reflects the intracellular",
"      <span class=\"nowrap\">",
"       NADH/NAD",
"      </span>",
"      ratio and, in theory, should be elevated in patients with aerobic energy metabolism defects (eg, respiratory chain complex defects) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/21\">",
"       21",
"      </a>",
"      ]. In practice, however, the calculation of this ratio in blood is usually not helpful when single organs are affected. In addition, the measurement of pyruvate levels in clinical laboratories is not reliable. Determination of the",
"      <span class=\"nowrap\">",
"       lactate/pyruvate",
"      </span>",
"      ratio in skin fibroblast tissue culture is more accurate.",
"     </li>",
"     <li>",
"      The ketone body ratio",
"      <span class=\"nowrap\">",
"       (beta-hydroxybutyrate/acetoacetate)",
"      </span>",
"      measured in blood reflects the intramitochondrial",
"      <span class=\"nowrap\">",
"       NADH/NAD",
"      </span>",
"      ratio and hence may be increased with defects involving the respiratory chain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/21\">",
"       21",
"      </a>",
"      ]. The finding of elevated blood serum alanine reduces the possibility that concomitant lactate elevation is artifactual. Other biochemical indicators of mitochondrial dysfunction include increased excretion of ethylmalonic acid and 3-methylglutaconic acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated excretion of citric acid cycle intermediates such as aconitate and succinate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lipid metabolism defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with a suspected lipid metabolism defect, the determination of plasma total and free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , serum acylcarnitines, urine acylglycines, and organic acids should preferably be performed during episodes of acute catabolic crises or periods of fasting. This is important because normal values may be observed when the patient is metabolically stable and not fasting. A fasting study is",
"    <strong>",
"     not",
"    </strong>",
"    recommended given the possibility of precipitating an acute catabolic crisis leading to death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a fatty acid metabolism disorder is supported by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of hypoketosis and hypoglycemia.",
"     </li>",
"     <li>",
"      A serum free fatty acid (in",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to ketone (beta-hydroxybutyrate, in",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      ratio of more than 2:1 (the normal ratio is 1:1). Beta-hydroxybutyrate constitutes about 80 percent of serum ketones and is sufficient for calculating this ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Specific abnormalities in serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      concentrations (",
"      <a class=\"graphic graphic_table graphicRef70936 \" href=\"UTD.htm?31/4/31819\">",
"       table 5",
"      </a>",
"      ). In carnitine uptake defects, the total serum carnitine is very low. In comparison, total serum carnitine concentrations are usually normal or low in fatty acid metabolism defects, except for CPT I deficiency, a disorder in which they may be normal or increased due to defective esterification of long-chain fatty acids to carnitine. In addition, the ratio of free carnitine to total carnitine is usually normal or low in most fatty acid metabolism defects, except for CPT I deficiency in which the ratio is high [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/22\">",
"       22",
"      </a>",
"      ]. If serum acylcarnitines are elevated, the further separation and identification of the individual acylcarnitine profile could prove useful in the diagnosis of specific defects. Acylcarnitines can be measured from dried blood spots using tandem mass spectroscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An amount of dicarboxylic acids (DCAs) which is equal to or higher than the amount of ketones (if the urine specimen was obtained after a period of fasting). However, the absence of DCAs in the urine does not rule out a fatty acid metabolism defect. The type of excreted DCAs may also help in the identification of the specific metabolic defect [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The finding of specific acylglycines in small quantities in the urine with some fatty acid metabolism defects. These include short-chain acyl-CoA dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), electron transfer flavoprotein (ETF), and ETF-coenzyme Q oxidoreductase deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with fixed weakness, electromyography may be useful in excluding a neuropathic process and providing evidence for a myopathic condition. Myotonic discharges may be observed in patients with myophosphorylase, acid maltase, and debrancher enzyme deficiency. In patients with excessive fatigability, repetitive nerve stimulation may be instrumental in excluding a defect in neuromuscular transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13962?source=see_link&amp;anchor=H9468271#H9468271\">",
"     \"Electrodiagnostic evaluation of the neuromuscular junction\", section on 'Repetitive nerve stimulation (RNS)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Forearm exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both anaerobic (ischemic) and aerobic forearm exercise testing may be helpful in evaluating patients suspected of having some type of metabolic myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ischemic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forearm ischemic exercise test should be performed if the clinical evaluation and laboratory findings suggest an enzymatic defect in the nonlysosomal glycogenolytic pathway and in glycolysis. This test may be useful in assessing all patients with exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/24\">",
"     24",
"    </a>",
"    ]. However, children younger than five years of age may not be cooperative with the testing protocol.",
"   </p>",
"   <p>",
"    The test begins with the placement and stabilization of a needle in a superficial antecubital vein of the arm to be exercised. Resting blood samples are obtained for serum lactate, pyruvate, creatine kinase (CK), and ammonia. The blood pressure cuff is inflated to a level just above the diastolic pressure and the patient is asked to perform one per second hand grips with at least 75 percent of the maximum voluntary hand grip. The duration of this semi-ischemic exercise test is one minute in the absence of cramping, but the cuff should be immediately deflated if an acute cramp develops.",
"   </p>",
"   <p>",
"    Some recommend that the test be performed without the blood pressure cuff in place (ie, non-ischemic forearm exercise test) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, this method may be less specific and sensitive and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/27\">",
"     27",
"    </a>",
"    ]. Most inflate the cuff to a value intermediate between the systolic and diastolic blood pressures to permit systolic blood flow. In certain patients, inflation of the blood pressure cuff above the systolic pressure and, rarely, even above the diastolic pressure carries some risk of focal rhabdomyolysis, myoglobinuria, and acute compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/28\">",
"     28",
"    </a>",
"    ]. Therefore, this test should be conducted with caution and never under total ischemic conditions.",
"   </p>",
"   <p>",
"    If the patient tolerates the test and exercises adequately, a single blood sample of CK and sequential samples of lactate, pyruvate, and ammonia are obtained at intervals of 1, 2, 3, 5, and 10 minutes after one minute of intermittent handgrip exercise. In normal individuals after a good effort, a three- to five-fold rise in lactate is noted within the first one to three minutes. The rise in serum ammonia is similar, but somewhat slower and more robust (5- to 10-fold over baseline); ammonia reaches a peak at three to four minutes.",
"   </p>",
"   <p>",
"    Various abnormalities in the forearm ischemic exercise test may be observed with different metabolic disorders (",
"    <a class=\"graphic graphic_table graphicRef71745 \" href=\"UTD.htm?12/31/12796\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rise in lactate is less than two-fold among patients with inborn errors of",
"      <span class=\"nowrap\">",
"       glycolysis/glycogenolysis;",
"      </span>",
"      however, the increase in ammonia is normal in patients who have made sufficient effort during the test.",
"     </li>",
"     <li>",
"      Lactate production may be absent or diminished in phosphorylase, phosphofructokinase, debrancher, phosphoglycerate mutase, phosphoglycerate kinase, and lactate dehydrogenase enzyme deficiencies. In the last condition, there is no rise in lactate levels, but pyruvate levels rise normally.",
"     </li>",
"     <li>",
"      The lactate curve is normal in acid maltase and in most cases of phosphorylase b kinase deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"       1",
"      </a>",
"      ], probably related to differential activation mechanisms for muscle phosphorylase [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with mitochondrial myopathies, there may be excessive production of lactate at submaximal levels of effort, but this is not a universal finding. With the non-ischemic forearm exercise test, the production of lactate is not sufficiently specific or sensitive for the diagnosis of mitochondrial disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With myoadenylate deaminase deficiency, there is absence of ammonia production with normal responses of venous lactate and pyruvate.",
"     </li>",
"     <li>",
"      The level of CK may rise in both",
"      <span class=\"nowrap\">",
"       glycogenolytic/glycolytic",
"      </span>",
"      and fatty acid oxidation defects. The forearm ischemic exercise test is normal in defects of fatty acid metabolism as far as the lactate and ammonia curves are concerned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aerobic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less experience with aerobic forearm exercise testing, but it may be a valuable method for differentiating mitochondrial myopathies from muscular dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aerobic forearm exercise test begins with a determination of a patient's maximal voluntary hand grip or maximal voluntary contraction (MVC), using a dynamometer or a rolled sphygmomanometer cuff. Once an estimate of the MVC is made, the patient is allowed to rest for 30 minutes. Meanwhile, a venous cannula is placed in the antecubital vein, and a baseline sample of blood is obtained and refrigerated for later blood gas analysis. After the baseline sample has been obtained, exercise is begun (40 percent of MVC for one second alternating with one second of rest) and continued for three minutes. Additional blood samples are obtained during exercise at one minute intervals for three minutes. The venous blood samples are then analyzed for their oxygen saturation.",
"   </p>",
"   <p>",
"    Using the technique described above, 12 patients with various forms of mitochondrial myopathy had a mean decrease of only 7 percent (range +15 to -32 percent) while 12 healthy subjects and 10 patients with muscular dystrophy had mean decreases in antecubital vein oxygen saturation during exercise of 43 percent and 38 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/905/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no overlap between the decrease in oxygen saturation of either healthy subjects (-34 to -54 percent) or muscular dystrophy (-33 to -54 percent) when compared to values obtained for those with mitochondrial myopathies. The need for blood gas analysis limits this test to sites with such equipment. Children may not be able to cooperate with the testing protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A muscle biopsy should be performed only after obtaining preliminary blood and urine tests, and, in some patients, electromyography and a forearm ischemic exercise test. Given the impracticality of testing muscle biopsy tissue for all known metabolic defects, the initial clinical and laboratory assessment helps target subsequent immunohistochemical and biochemical testing of muscle tissue.",
"   </p>",
"   <p>",
"    Microscopic examination of the muscle sample should include electron microscopy, and immunohistochemical staining for phosphorylase, phosphofructokinase, and myoadenylate deaminase, if deficiencies in these enzymes are diagnostic possibilities. Microscopic examination will determine the presence or absence of glycogen or lipid storage, or ragged-red fibers in mitochondrial myopathies.",
"   </p>",
"   <p>",
"    Since all of these evaluations will be normal in a number of metabolic defects, additional biochemical evaluation of muscle tissue should be pursued through commercial or research laboratories. In this setting, analysis will need to be focused on specific possible biochemical defects, based upon the results of the preliminary noninvasive evaluation. In some instances, it may be possible to perform the direct enzymatic assay in cultured skin fibroblasts. This assay will be profitable diagnostically only if the enzymatic defect is expressed in this cell type. In the author&rsquo;s clinical experience, extensive investigations including a muscle biopsy for microscopic and biochemical evaluation are frequently unrevealing, with diagnostic yield of less than 15 percent. Because of the relatively low yield, a muscle biopsy is often not obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Molecular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific defects can be characterized at the molecular level either by Western blotting or by molecular analysis of specific mutations. Western blotting can be used to differentiate between a kinetic deficiency versus a defect in the production of the relevant enzyme. The identification of specific mutations can be used to precisely and rapidly detect specific defects, as well as presymptomatic or prenatal diagnosis and carrier detection. It is advisable to order DNA testing before performing a muscle biopsy if a specific defect is suspected (eg, myophosphorylase or CPT II deficiency).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"       \"Patient information: Rhabdomyolysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H400794804\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The symptoms, signs, and laboratory abnormalities resulting from a metabolic myopathy vary with the underlying defect. The diagnosis of these disorders depends upon a constellation of findings, including the type of muscle involvement, specific laboratory abnormalities (particularly elevations in serum creatine kinase and myoglobinuria), patient age, family history, and the results of histologic and pathologic examinations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inherited disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (",
"      <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"       table 1",
"      </a>",
"      ). The age of onset varies from birth to adulthood. The principal symptoms and signs, however, are those related to exercise intolerance and recurrent myoglobinuria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Disorders of glycogen metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolic myopathies resulting from disorders of lipid metabolism include defects of beta-oxidation enzymes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency syndromes, and fatty acid transport defects. The free fatty acids cannot be metabolized because of the existing metabolic block; as a result, they are stored in the cytoplasm as triglycerides, thereby resulting in progressive lipid storage myopathy with weakness, hypertrophic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dilated cardiomyopathy, and fatty liver. Symptoms are usually induced by prolonged exercise and prolonged fasting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disorders of lipid metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise intolerance due to premature fatigue is a common manifestation of mitochondrial diseases. (See",
"      <a class=\"local\" href=\"#H400795808\">",
"       'Mitochondrial disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common metabolic cause of recurrent myoglobinuria in both adults and children is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyltransferase II deficiency. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myoglobinuria and rhabdomyolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A general approach to the diagnosis of metabolic myopathies is presented in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef71018 \" href=\"UTD.htm?18/38/19044\">",
"       algorithm 1",
"      </a>",
"      ). Most patients with a metabolic myopathy (eg, glycogen storage diseases,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyltransferase deficiency) have dynamic rather than static symptoms, and therefore usually complain of exercise intolerance, muscle pain and cramps rather than fixed weakness with exercise. Nevertheless, some patients may develop progressive muscular weakness that is usually proximal in distribution. In a smaller group of patients, both dynamic and static symptoms predominate (",
"      <a class=\"graphic graphic_table graphicRef59733 \" href=\"UTD.htm?8/50/9004\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H400795568\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptom assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory investigation (",
"      <a class=\"graphic graphic_table graphicRef56365 \" href=\"UTD.htm?10/4/10317\">",
"       table 4",
"      </a>",
"      ) of patients with suspected metabolic myopathies includes serum and urine testing (",
"      <a class=\"graphic graphic_table graphicRef70936 \" href=\"UTD.htm?31/4/31819\">",
"       table 5",
"      </a>",
"      ), electromyography, the forearm exercise test (",
"      <a class=\"graphic graphic_table graphicRef71745 \" href=\"UTD.htm?12/31/12796\">",
"       table 6",
"      </a>",
"      ), and in some cases, muscle biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      molecular genetic testing. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Serum and urine testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Electromyography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Forearm exercise testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/1\">",
"      Tein I. Metabolic myopathies. Semin Pediatr Neurol 1996; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/2\">",
"      Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/3\">",
"      Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010; 10:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/4\">",
"      Haller RG, Vissing J. Spontaneous \"second wind\" and glucose-induced second \"second wind\" in McArdle disease: oxidative mechanisms. Arch Neurol 2002; 59:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/5\">",
"      Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 2004; 62:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/6\">",
"      Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 1991; 324:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/7\">",
"      Bell AW, Thompson GE. Free fatty acid oxidation in bovine muscle in vivo: effects of cold exposure and feeding. Am J Physiol 1979; 237:E309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/8\">",
"      Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/9\">",
"      Tein I, De Vivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res 1990; 28:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/10\">",
"      Stanley CA, DeLeeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991; 30:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/11\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/12\">",
"      Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 2006; 118:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/13\">",
"      van Adel BA, Tarnopolsky MA. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/14\">",
"      Kollberg G, Moslemi AR, Lindberg C, et al. Mitochondrial myopathy and rhabdomyolysis associated with a novel nonsense mutation in the gene encoding cytochrome c oxidase subunit I. J Neuropathol Exp Neurol 2005; 64:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/15\">",
"      Kwon JH, Kim JS. Rhabdomyolysis in a patient with MELAS syndrome. Eur Neurol 2003; 50:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/16\">",
"      McFarland R, Taylor RW, Chinnery PF, et al. A novel sporadic mutation in cytochrome c oxidase subunit II as a cause of rhabdomyolysis. Neuromuscul Disord 2004; 14:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/17\">",
"      Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr 1990; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/18\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/19\">",
"      Aboumousa A, Hoogendijk J, Charlton R, et al. Caveolinopathy--new mutations and additional symptoms. Neuromuscul Disord 2008; 18:572.",
"     </a>",
"    </li>",
"    <li>",
"     Griggs, R, Mendell, J, Miller, R. Metabolic myopathies. In: Evaluation and Treatment of Myopathies, Griggs, R, Mendell, J, Miller, R (Eds), FA Davis, Philadelphia 1995. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/21\">",
"      Das AM, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies. J Biomed Biotechnol 2010; 2010:340849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/22\">",
"      Vockley J. The changing face of disorders of fatty acid oxidation. Mayo Clin Proc 1994; 69:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/23\">",
"      Mortensen PB, Gregersen N. The biological origin of ketotic dicarboxylic aciduria. II. In vivo and in vitro investigations of the beta-oxidation of C8-C16-dicarboxylic acids in unstarved, starved and diabetic rats. Biochim Biophys Acta 1982; 710:477.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1994. p.1554.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/25\">",
"      Hogrel JY, Lafor&ecirc;t P, Ben Yaou R, et al. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001; 56:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/26\">",
"      Kazemi-Esfarjani P, Skomorowska E, Jensen TD, et al. A nonischemic forearm exercise test for McArdle disease. Ann Neurol 2002; 52:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/27\">",
"      Hanisch F, Eger K, Bork S, et al. Lactate production upon short-term non-ischemic forearm exercise in mitochondrial disorders and other myopathies. J Neurol 2006; 253:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/28\">",
"      Lindner A, Reichert N, Eichhorn M, Zierz S. Acute compartment syndrome after forearm ischemic work test in a patient with McArdle's disease. Neurology 2001; 56:1779.",
"     </a>",
"    </li>",
"    <li>",
"     Bruno, C, Hays, AP, DiMauro, S. Glycogen storage diseases of muscle. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones, HR Jr, De Vivo, DC, Darras, BT (Eds), Butterworth Heinemann, Philadelphia 2003. p.813.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/30\">",
"      &Oslash;rngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008; 70:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/31\">",
"      Haller RG. Fueling around with glycogen: the implications of muscle phosphorylase b kinase deficiency. Neurology 2008; 70:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/905/abstract/32\">",
"      Jensen TD, Kazemi-Esfarjani P, Skomorowska E, Vissing J. A forearm exercise screening test for mitochondrial myopathy. Neurology 2002; 58:1533.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6193 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_905=[""].join("\n");
var outline_f0_56_905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H400794804\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Disorders of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disorders of lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H400795808\">",
"      Mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myoglobinuria and rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H400795568\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serum and urine testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lipid metabolism defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Forearm exercise testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ischemic exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aerobic exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H400794804\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6193|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/38/19044\" title=\"algorithm 1\">",
"      Approach to metabolic myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/58/25515\" title=\"table 2\">",
"      Metabolic myopathy and rhabdo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/50/9004\" title=\"table 3\">",
"      Myopathy and biochemical defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/4/10317\" title=\"table 4\">",
"      Evaluation metabolic myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/4/31819\" title=\"table 5\">",
"      Carnitine in disorders of fatty acid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/31/12796\" title=\"table 6\">",
"      Ischemic forearm exercise test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13962?source=related_link\">",
"      Electrodiagnostic evaluation of the neuromuscular junction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=related_link\">",
"      Energy metabolism in muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=related_link\">",
"      Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_906="Paraneoplastic and autoimmune encephalitis";
var content_f0_56_906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraneoplastic and autoimmune encephalitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/906/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/906/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/906/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/906/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/56/906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/56/906/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/56/906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3369874\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle, either damaging one area or multiple areas.",
"   </p>",
"   <p>",
"    Limbic encephalitis refers to an inflammatory process localized to structures of the limbic system that produces cognitive impairment along with disordered perception, mood changes, and sleep disturbances. The pathology and clinical and radiological findings are often not confined to these areas, however. Both paraneoplastic and nonparaneoplastic encephalitis share many clinical features and also have some that are distinctive. Response to treatment can be dramatic but is highly variable.",
"   </p>",
"   <p>",
"    This topic discusses paraneoplastic and autoimmune encephalitis. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370740\">",
"    <span class=\"h1\">",
"     CLINICAL AND PATHOLOGICAL OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic encephalomyelitis is characterized by involvement of several areas of the nervous system, including the temporal-limbic regions, brainstem, cerebellum, spinal cord, dorsal root ganglia, and autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The distribution of disease and symptoms varies.",
"   </p>",
"   <p>",
"    Pathologic examination usually reveals perivascular and interstitial inflammatory infiltrates of T lymphocytes, gliosis, neuronophagic nodules, and loss of neurons. In addition to T-cell infiltrates, B-cells preferentially cluster around vessels and may be associated with plasma cell infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The findings are typically more extensive than symptoms would suggest and may involve any area of the central nervous system, dorsal root ganglia, or autonomic neurons.",
"   </p>",
"   <p>",
"    Most patients with paraneoplastic encephalomyelitis have anti-Hu antibodies (also called antineuronal nuclear antibodies or ANNA-1) (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. These antibodies are directed against neuron specific RNA-binding nuclear proteins (",
"    <a class=\"graphic graphic_picture graphicRef56327 \" href=\"UTD.htm?30/24/31110\">",
"     picture 1",
"    </a>",
"    ) and are associated with paraneoplastic sensory neuronopathy as well as encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ]. The expression of the target antigens is highly restricted to the nervous system and the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually all cancer types have been associated with paraneoplastic encephalomyelitis or its variants (limbic encephalitis, brainstem encephalitis, myelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, the underlying tumor is small cell lung cancer (SCLC) in approximately 75 percent of patients. This has been confirmed in four large series comprising over 500 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,5,6,8\">",
"     1,5,6,8",
"    </a>",
"    ]. The tumor is frequently undiagnosed at the time that the neurologic syndrome develops and may be difficult to demonstrate because of its small size. This stands in direct contrast to the fact that most SCLCs (over 60 percent) are widely metastatic at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370747\">",
"    <span class=\"h2\">",
"     Myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic myelitis occurs as part of encephalomyelitis, usually with SCLC. These patients often develop sensory neuronopathy (ie, involvement of the dorsal root ganglia) as well and have anti-Hu antibodies in their serum and cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Motor neuron syndromes are also described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370754\">",
"    <span class=\"h2\">",
"     Limbic encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic and autoimmune limbic encephalitis (LE) is characterized by acute or subacute mood and behavioral changes, short-term memory problems, complex-partial seizures, and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Hypothalamic dysfunction may also occur with manifestations such as hyperthermia, somnolence, and endocrine abnormalities. Approximately two-thirds of patients with LE develop multifocal involvement of the nervous system (eg, encephalomyelitis). Symptoms typically evolve over days to weeks; but more indolent presentations over months have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/9\">",
"     9",
"    </a>",
"    ]. While most case series are of adult patients, children as young as three years have been reported with LE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroencephalographic findings include focal or generalized slowing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epileptiform activity, which is maximal in the temporal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/10\">",
"     10",
"    </a>",
"    ]. MRI may show areas of hyperintensity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contrast enhancement in the medial temporal lobes. Positron emission tomography may demonstrate hypermetabolism in the medial temporal lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent neoplasms associated with paraneoplastic LE are cancer of the lung (usually SCLC), seminoma and other testicular tumors, thymoma, breast cancer, and Hodgkin lymphoma. Neurologic symptoms typically precede discovery of the tumor by weeks or months. The type of associated autoantibody varies with tumor type (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ). With small cell lung cancer, most patients have anti-Hu or",
"    <span class=\"nowrap\">",
"     CV2/CRMP5",
"    </span>",
"    antibodies in their serum and CSF, and they are more likely to develop other manifestations of paraneoplastic encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3372592\">",
"    <span class=\"h2\">",
"     Brainstem encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic brainstem dysfunction often occurs during the course of other paraneoplastic syndromes, such as limbic encephalitis, cerebellar degeneration, or multifocal encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1\">",
"     1",
"    </a>",
"    ]. In some patients, however, the neurologic symptoms and pathologic findings (such as perivascular and interstitial infiltrates, gliosis, and loss of neurons) appear restricted to the brainstem (",
"    <a class=\"graphic graphic_picture graphicRef60351 \" href=\"UTD.htm?39/48/40711\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/2\">",
"     2",
"    </a>",
"    ]. The term rhombencephalitis is sometimes used to denote inflammatory conditions affecting the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A wide spectrum of symptoms localized to the pons",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medulla can develop in these patients, including supranuclear, internuclear, and nuclear extraocular movement deficits, opsoclonus, nystagmus, dysphagia, dysarthria, sensorineural deafness, trigeminal sensory loss, central hypoventilation, and vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. Many different underlying tumors have been identified.",
"   </p>",
"   <p>",
"    Any of the antibodies seen in paraneoplastic encephalomyelitis can be associated with predominant brainstem dysfunction (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ). Patients with SCLC typically have anti-Hu antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,16\">",
"     1,16",
"    </a>",
"    ], while most patients with testicular cancer have anti-Ma2 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/17\">",
"     17",
"    </a>",
"    ]. Anti-Hu brainstem encephalitis has also been described in association with breast cancer, hypernephroma, and prostate adenocarcinoma, and rarely, in patients who appear cancer-free [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3372409\">",
"    <span class=\"h1\">",
"     SPECIFIC ANTIBODY-RELATED SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3372425\">",
"    <span class=\"h2\">",
"     Antibodies to intracellular antigens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3373108\">",
"    <span class=\"h3\">",
"     Anti-Hu encephalomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Hu (also known as antineuronal nuclear antibody, type 1, ANNA-1) paraneoplastic syndromes are often multifocal, affecting temporal lobes, brainstem, cerebellum, dorsal roots,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,5,8,9\">",
"     1,5,8,9",
"    </a>",
"    ]. In many patients, symptoms begin with, and may remain restricted, to the dorsal root ganglia, causing a subacute sensory neuronopathy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link&amp;anchor=H8#H8\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\", section on 'Subacute sensory neuronopathy'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Other patients present with a more restricted brainstem or limbic encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. A presentation with nonconvulsive seizures has been described in a number of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A small cell lung cancer (SCLC) is almost found in most patients with encephalitis and anti-Hu antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Some patients have other cancer-types; no cancer is found in approximately 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early recognition of paraneoplastic encephalomyelitis and prompt antitumor treatment are important in stabilizing or sometimes improving the neurologic symptoms. In one series of 200 patients with paraneoplastic encephalomyelitis and anti-Hu antibodies, antitumor treatment was associated with a significantly greater likelihood of neurologic improvement or stabilization (odds ratio, 4.56) and a lower mortality rate (relative risk of death in the absence of treatment 2.56) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/5\">",
"     5",
"    </a>",
"    ]. Immunotherapy (eg, corticosteroids, immune globulin, plasma exchange, etc.) either given with antitumor treatment or alone has also been associated with stabilization in a smaller proportion of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. One report describes improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in two patients with paraneoplastic encephalomyelitis associated with the anti-Hu antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic dysfunction is a frequent cause of death, particularly when there is brainstem and autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/1\">",
"     1",
"    </a>",
"    ]. However, prolonged survival can occur in association with regression of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. Neurologic function rarely improves spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370761\">",
"    <span class=\"h3\">",
"     Ma2-associated encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer is associated with anti-Ma2 (also called anti-Ta) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/17\">",
"     17",
"    </a>",
"    ]. The Ma2 antigen is selectively expressed in neurons and the testicular tumor (",
"    <a class=\"graphic graphic_picture graphicRef56327 \" href=\"UTD.htm?30/24/31110\">",
"     picture 1",
"    </a>",
"    ). Ma2 shares homology with Ma1, a gene that is associated with other paraneoplastic neurologic syndromes, particularly brainstem and cerebellar dysfunction (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/4,26\">",
"     4,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of Ma2 associated encephalitis differs from classic paraneoplastic limbic encephalitis (LE). In a series of 38 patients with anti-Ma2 encephalitis, 34 (89 percent) developed isolated or combined limbic (n=27), diencephalic (n=13) or brainstem encephalopathy (n=25) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/4\">",
"     4",
"    </a>",
"    ]. MRI abnormalities were frequent in these brain regions, and inflammatory changes were typically present in the CSF. Four patients developed other syndromes, including two with a predominant cerebellar ataxia that remained stable for several years, and two with myelopathy.",
"   </p>",
"   <p>",
"    Other prominent neurologic features included excessive daytime sleepiness and eye movement abnormalities, particularly a vertical gaze paresis that sometimes evolved to total external ophthalmoplegia. Three patients developed atypical parkinsonism, and two developed a severe hypokinetic syndrome. An additional case report describes an individual whose syndrome included amyotrophy of the upper extremities with an associated cervical cord lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testicular germ cell tumors are the most common associated neoplasm, found in 18 of 34 patients found to have cancer in the above described series [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/4\">",
"     4",
"    </a>",
"    ]. Orchiectomy may be required to reveal microscopic testicular germ cell neoplasia in this setting, as was true in six men (age 26 to 40 years) with Ma2-associated encephalitis and no evidence of other cancer by other rigorous testing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/28\">",
"     28",
"    </a>",
"    ]. All six men were identified to be at risk for testicular cancer because of new testicular enlargement, testicular microcalcifications,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cryptorchidism. Extragonadal germ cell tumors have also been described in association with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/29\">",
"     29",
"    </a>",
"    ]. The diagnosis of testicular germ cell tumors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coexisting antibodies to Ma1 were seen in 15 of 34 patients with Ma2 encephalitis and were significantly more common in patients with tumors other than testicular cancer (usually lung cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/4\">",
"     4",
"    </a>",
"    ]. Compared with patients with antibodies only to Ma2, these patients are also more likely to develop ataxia and to have a worse prognosis.",
"   </p>",
"   <p>",
"    Ma2 associated encephalitis is more responsive to oncologic and immunologic treatment than other types of paraneoplastic encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/29\">",
"     29",
"    </a>",
"    ]. In the series cited above, neurologic improvement or stabilization occurred in 18 of 33 patients with outcome information [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/4\">",
"     4",
"    </a>",
"    ]. Features significantly associated with improvement or stabilization included male sex, age 45 years or less, testicular tumour with complete response to treatment, absence of anti-Ma1 antibodies, and limited CNS involvement. However, a positive treatment response can occur in other patients as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5281280\">",
"    <span class=\"h3\">",
"     Anti-CRMP5 encephalomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to a collapsin-responsive mediator protein-5 (CRMP5) have been associated with a paraneoplastic encephalitis. Cortical symptoms are often not confined to the limbic system; distinctive symptoms including cerebellar ataxia, chorea, cranial neuropathies, loss of olfaction and taste,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    optic neuropathy are described in some affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. The most common associated cancers are SCLC and thymoma. Improvement with anticancer therapy and corticosteroids has been described. Other paraneoplastic syndromes associated with these antibodies include axonal sensorimotor neuropathy, uveitis, and optic neuritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12091957\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic stiff-person syndrome is associated with anti-amphiphysin antibodies. This disorder may be accompanied by encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link&amp;anchor=H6#H6\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\", section on 'Stiff-person syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immune responses to intracellular antigens have been identified in a few patients with limbic encephalitis (CRMP3-4, adenylate kinase 5, BR",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase, glutamate receptor 2, and Ri) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. Other intracellular antigens remain to be characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370782\">",
"    <span class=\"h2\">",
"     Antibodies to synaptic proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group of disorders is associated with autoimmunity to synaptic proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/42\">",
"     42",
"    </a>",
"    ]. The target antigens play critical roles in neuronal transmission and plasticity. These syndromes are variably associated with cancer as noted below.",
"   </p>",
"   <p>",
"    While patients are often severely affected, these disorders are highly responsive to immunomodulatory therapies. At this time, treatment approach to these patients is based on the experience with patients with anti-NMDA receptor encephalomyelitis, which is the largest group studied to date. Some cell surface antigens associated with a limbic encephalitis remain to be characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370789\">",
"    <span class=\"h3\">",
"     Anti-NMDA receptor encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is associated with a predictable set of symptoms that combine to make up a characteristic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/43-50\">",
"     43-50",
"    </a>",
"    ]. Many patients present with prodromal headache, fever, or a viral-like process, followed in a few days by a multistage progression of symptoms that include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prominent psychiatric manifestations: anxiety, agitation, bizarre behavior, hallucinations, delusions, disorganized thinking",
"     </li>",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Memory deficits",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Decreased level of consciousness, stupor with catatonic features",
"     </li>",
"     <li>",
"      Frequent dyskinesias: orofacial, choreoathetoid movements, dystonia, rigidity, opisthotonic postures",
"     </li>",
"     <li>",
"      Autonomic instability: hyperthermia, fluctuations of blood pressure, tachycardia, bradycardia, cardiac pauses, and sometimes hypoventilation requiring mechanical ventilation.",
"     </li>",
"     <li>",
"      Language dysfunction: diminished language output, mutism. Echolalia is often noted in the early stages or in the recovery phase of the disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may require intensive care support for several weeks or months, and afterwards a multidisciplinary team including physical rehabilitation and psychiatric management of protracted behavioral symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/46,48,51\">",
"     46,48,51",
"    </a>",
"    ]. The latter include symptoms of frontal lobe dysfunction (poor attention and planning, impulsivity, behavioral disinhibition, memory deficits) that progressively improve over months. Milder forms of the disorder have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Accompanying opsoclonus-myoclonus has been described in at least two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Of note, isolated opsoclonus-myoclonus without encephalitis has been described in patients with ovarian teratoma, but these patients do not have NMDAR antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children as young as 23 months have been reported with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/49,57\">",
"     49,57",
"    </a>",
"    ]. The symptoms are similar to those of the adults, although dysautonomia and hypoventilation are less frequent or severe. Presenting symptoms usually include acute behavioral change, seizures, language dysfunction, dystonia, or dyskinesias.",
"   </p>",
"   <p>",
"    The differential diagnosis of this clinical presentation includes primary psychiatric disorders (psychosis or schizophrenia), malignant catatonia, neuroleptic malignant syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/58\">",
"     58",
"    </a>",
"    ], viral encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/59\">",
"     59",
"    </a>",
"    ], and encephalitis lethargica [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/60\">",
"     60",
"    </a>",
"    ], among others [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/61\">",
"     61",
"    </a>",
"    ]. A study examining the serum or CSF of 20 patients (mostly children) that had been considered to have \"idiopathic encephalitis with dyskinesias\" showed that 10 (50 percent) had anti-NMDAR encephalitis. A similar study examining patients with dyskinetic \"encephalitis lethargica\", a descriptive term that likely includes several forms of idiopathic encephalitis, showed that 20 of 20 patients had anti-NMDAR encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder should be suspected in adults or children that develop the above symptoms usually accompanied by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF lymphocytic pleocytosis or oligoclonal bands (although CSF can be normal initially).",
"     </li>",
"     <li>",
"      EEG with infrequent epileptic activity, but frequent slow, disorganized activity that does not correlate with most abnormal movements.",
"     </li>",
"     <li>",
"      Brain MRI that is often normal or shows transient FLAIR or contrast enhancing abnormalities in cortical (brain, cerebellum) or subcortical regions (hippocampus, basal ganglia, white matter) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/48,57\">",
"       48,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of anti-NMDAR encephalitis is confirmed by the detection of antibodies to NR1 subunit of the NMDAR in serum or CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/62\">",
"     62",
"    </a>",
"    ]. At presentation, serum and CSF are usually positive; most patients have intrathecal synthesis of antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/63\">",
"     63",
"    </a>",
"    ]. After treatment or in advanced stages of the disease, the CSF antibodies usually remain elevated if there is no clinical improvement, while serum antibodies may be substantially decreased by treatments. The titer of CSF antibodies appears to correlate more closely with the clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/47,48,57\">",
"     47,48,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The detection of an ovarian teratoma is age-dependant; approximately 50 percent of female patients older than 18 have uni- or bilateral ovarian teratomas while less than 9 percent of girls younger than 14 years have a teratoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/57,62\">",
"     57,62",
"    </a>",
"    ]. A review of 400 cases showed that African-American patients have a mild predominance to have ovarian teratomas compared with patients from other ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/50\">",
"     50",
"    </a>",
"    ]. Ovarian teratomas are often revealed by MRI and CT of the abdomen and pelvis, along with abdominal or transvaginal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H9#H9\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Teratomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In male patients the detection of a tumor is rare. Cases with associated tumors other than ovarian teratoma include testicular germ cell tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/42\">",
"     42",
"    </a>",
"    ], teratoma of the mediastinum, SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/48\">",
"     48",
"    </a>",
"    ], Hodgkin's lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/15\">",
"     15",
"    </a>",
"    ], and neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/64\">",
"     64",
"    </a>",
"    ]. Preceding infections (mycoplasma, varicella zoster) have been suspected to play a role in cases of nonparaneoplastic, presumed auto-immune anti-NMDA receptor encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resection of the tumor, glucocorticoids, intravenous immune globulin, and plasma exchange often result in improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/44,47,48,53,57,65\">",
"     44,47,48,53,57,65",
"    </a>",
"    ]. Patients who do not improve with these first line therapies (often cases without tumor) may improve with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/48,57,65,66\">",
"     48,57,65,66",
"    </a>",
"    ]. Progressive neurologic deterioration and death can occur without treatment. However, spontaneous recovery has also been described in a few patients after several months of severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/46\">",
"     46",
"    </a>",
"    ]. Our approach is to use concurrent immune globulin",
"    <span class=\"nowrap\">",
"     (0.4g/kg",
"    </span>",
"    daily for five days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1 gram daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/50\">",
"     50",
"    </a>",
"    ]. We prefer this to plasma exchange which can be difficult to implement in children and agitated patients as well as patients with autonomic instability. If there is no significant clinical improvement after 10 days, we start second line therapy; for adults we use rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every week for four weeks) combined with cyclophosphamide (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given with the first dose of rituximab), followed by monthly cycles of cyclophosphamide. Children are generally treated with just one of these agents, usually rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/49\">",
"     49",
"    </a>",
"    ]. Treatment is continued until substantial recovery occurs.",
"   </p>",
"   <p>",
"    Patients with anti-NMDA receptor encephalitis are at risk for relapse, and may require longer duration of immunosuppression. Relapse occurs in 15 to 24 percent of the patients, sometimes after several years, and is often associated with occult or relapsing teratoma or with the absence of a tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/48,49,57,67\">",
"     48,49,57,67",
"    </a>",
"    ]. In one series, relapses were more common among those who did not receive immunotherapy with the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/67\">",
"     67",
"    </a>",
"    ]. We generally continue immunosuppressive therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) for at least one year after initial immunotherapies are discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370796\">",
"    <span class=\"h3\">",
"     Encephalitis and LGI1 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder was previously attributed to antibodies to voltage gated potassium channel (VGKC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/68\">",
"     68",
"    </a>",
"    ]. The true target antigen has been shown to be leucine rich glioma inactivated 1 (LGI1) secreted neuronal protein that functions as a ligand for two epilepsy-related proteins, ADAM22 and ADAM23 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients develop memory disturbances, confusion, and seizures. Memory and cognitive deficits may be preceded by short tonic seizures that can be mistaken for myoclonus or dystonia and often do not respond to antiepileptic drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Patients may develop hyponatremia or rapid eye movement sleep behavior disorders.",
"   </p>",
"   <p>",
"    MRI findings are usually typical of limbic encephalitis while CSF is often normal or only shows oligoclonal bands [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/72\">",
"     72",
"    </a>",
"    ]. Only 20 percent of cases are paraneoplastic; the most common associated tumors are thymoma or SCLC.",
"   </p>",
"   <p>",
"    Treatment with glucocorticoids, IVIG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma exchange result in significant improvement in 70 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/71,73-75\">",
"     71,73-75",
"    </a>",
"    ]. In our experience, complicating severe hyponatremia and nonconvulsive status epilepticus can be life-threatening and should be aggressively treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370803\">",
"    <span class=\"h3\">",
"     Encephalitis and AMPA receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few reports have described small case series of patients with a LE associated with a novel cell surface antigen, the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleprionic acid receptor (AMPAR) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, seven of ten patients had an underlying neoplasm (breast, thymus, or lung); three did not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/76\">",
"     76",
"    </a>",
"    ]. A lymphocytic pleocytosis in the CSF was identified in nine patients (range 6 to",
"    <span class=\"nowrap\">",
"     75/&micro;l).",
"    </span>",
"    MRI showed FLAIR signal abnormality in the medial temporal lobes in eight of nine patients examined. Nine patients responded to treatment of the underlying neoplasm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunotherapy, but subsequent relapses occurred in five (in the absence of tumor recurrence) and were associated with an incomplete treatment response and death from status epilepticus in one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370810\">",
"    <span class=\"h3\">",
"     Anti-GABA-B encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report, receptors against the B1 subunit of the gamma-aminobutyric acid (GABA-B) receptor were the most common antibodies found in LE associated with SCLC that were previously considered seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a separate series of 15 patients with a LE and anti-GABA-B receptor antibodies, seven patients had an underlying neoplasm (usually SCLC); eight patients did not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/80\">",
"     80",
"    </a>",
"    ]. MRI showed FLAIR and T2 signal abnormalities in 11 patients; a lymphocytic pleocytosis in the CSF was present in eight. Nine patients responded to treatment with immunotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the underlying tumor; four received no treatment and did not improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3370817\">",
"    <span class=\"h3\">",
"     Anti-CASPR-2 associated encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder was previously attributed to antibodies to VGKC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/68\">",
"     68",
"    </a>",
"    ]. The true antigen, contactin associated protein 2 (CASPR2), plays a role in maintaining the normal function of VGKC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients develop symptoms of encephalitis (cognitive impairment, memory loss, hallucinations, and seizures), peripheral nerve hyperexcitability, or both (Morvan&rsquo;s syndrome). The combination of symptoms can mistakenly lead to a diagnosis of an unusual form of motor neuron disease. Because anti-CASPR-2 associated encephalitis responds to immunotherapy, making the distinction is critical. CASPR2 antibody-associated syndromes may occur with or without an associated tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4565291\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case series of 15 patients with voltage gated potassium channel (VGKC) antibodies not directed against LGI1 or CASPR-2 describes prominent sleep disturbances (eg, severe insomnia, dream enactment) as the cardinal manifestation of the encephalitis along with other neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VGKC antibodies not directed against LGI1 or CASPR-2 were also found in four children ages 1 to 14 years with an encephalitis that presented with status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/83\">",
"     83",
"    </a>",
"    ]. One child had a complete recovery while the other three had cognitive sequelae",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporal lobe epilepsy with hippocampal sclerosis. Other case reports also suggest that limbic encephalitis may lead to hippocampal sclerosis or temporal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to the &alpha;-1 subunit of the glycine receptor have been associated with a syndrome of progressive encephalomyelitis with rigidity and myoclonus (PERM) acquired hyperekplexia, and an atypical stiff-person syndrome in patients without GAD antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. One patient had an associated thymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/88\">",
"     88",
"    </a>",
"    ]; other cases have not had cancer. Response to immunotherapy is variable. One patient who also had NMDA receptor antibodies died within two months of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3372498\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280997\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic disease affecting the brain or leptomeninges, viral encephalitis, Creutzfeldt Jakob disease, ischemic and hemorrhagic cerebrovascular disease, Whipple disease, psychiatric disease, and primary degenerative dementia have all been reported to cause a clinical syndrome for which the diagnosis of paraneoplastic or autoimmune LE was considered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/9,62,90,91\">",
"     9,62,90,91",
"    </a>",
"    ]. Patients who present more acutely may be considered to have Wernicke encephalopathy, toxic-metabolic encephalopathy, or nonconvulsive status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/61\">",
"     61",
"    </a>",
"    ]. The differential diagnosis in the more unusual subset of patients with predominant brainstem encephalitis includes multiple sclerosis, Behcet disease, Listeria infection, and tuberculosis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12091013\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with this clinical presentation will have neuroimaging, EEG, lumbar puncture, and serologic testing for appropriate biomarkers. An algorithmic approach to the diagnosis and treatment of paraneoplastic and autoimmune encephalitis is presented in the Figure (",
"    <a class=\"graphic graphic_algorithm graphicRef72802 \" href=\"UTD.htm?32/41/33438\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A brain MRI is helpful in this clinical setting to exclude a cerebrovascular event or metastatic disease, among others. Characteristic MRI findings in patients with paraneoplastic or autoimmune encephalitis include signal hyperintensities on FLAIR or T2-weighted images in affected brain regions, ie, medial temporal lobes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brainstem; subcortical regions and the cerebellum are sometimes affected as well. Contrast enhancement is variable. MRI findings are neither sensitive nor specific for these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An EEG should be performed in most cases to exclude nonconvulsive seizures. In patients with paraneoplastic and autoimmune encephalitis, nonspecific EEG abnormalities are common and include focal or generalized slowing, epileptiform activity, and periodic lateralized epileptiform discharges (PLEDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebrospinal fluid (CSF) examination should be performed and should include cell count, protein, and glucose; viral cultures and other studies to exclude viral infection and other pathogens should also be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link&amp;anchor=H11#H11\">",
"     \"Viral encephalitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .) Cytology should also be performed on the CSF to exclude leptomeningeal metastasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Diagnostic evaluation'",
"    </a>",
"    .) Patients with paraneoplastic and autoimmune encephalitis may have normal or abnormal CSF findings. Modest elevation of protein (&lt;100",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is the most common finding; a minority have a mild lymphocytic pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more marked elevations of protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolic and toxic encephalopathies should also be considered and excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute toxic-metabolic encephalopathy in adults\", section on 'Laboratory and imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paraneoplastic and autoimmune biomarkers should be sought in the patient's serum (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/62\">",
"     62",
"    </a>",
"    ]. Not all biomarkers have commercially available testing, and some antigens remain to be characterized. Thus, negative results do not exclude a paraneoplastic or autoimmune disorder. A sample of patient&rsquo;s CSF and serum should be sent to a research laboratory for examination in these cases. Other caveats regarding antibody testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Antibody screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient does not have a known cancer diagnosis, evaluation for occult malignancy should also ensue. Because SCLC comprises the majority of underlying neoplasms in older patients with limbic encephalitis, chest imaging should have a high priority in patients with this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380193\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithmic approach to the diagnosis and treatment of paraneoplastic and autoimmune encephalitis is presented in the Figure (",
"    <a class=\"graphic graphic_algorithm graphicRef72802 \" href=\"UTD.htm?32/41/33438\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific antineoplastic treatment may result in neurologic improvement.",
"   </p>",
"   <p>",
"    Immunosuppression (glucocorticoids, intravenous immune globulin, and plasma exchange) may help if the tumor is also treated and in non-paraneoplastic syndromes (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"UTD.htm?7/59/8125\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/13,92,93\">",
"     13,92,93",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may have efficacy when other immunotherapies do not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/50,94\">",
"     50,94",
"    </a>",
"    ]. Because of the risk of permanent sequelae, use of immunosuppressive therapy should not await cancer diagnosis or antibody characterization in patients with the characteristic clinical and radiologic presentation in whom infection, especially herpes simplex encephalitis, has been ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/95\">",
"     95",
"    </a>",
"    ]. There are no controlled studies of any form of immunotherapy in patients with paraneoplastic or autoimmune encephalitis. Our approach varies with the severity of the illness, the status of the underlying neoplasm, if present, and other factors. An approach for treatment of anti-NMDA receptor encephalitis is outlined above. (See",
"    <a class=\"local\" href=\"#H3370789\">",
"     'Anti-NMDA receptor encephalitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Seizures should be treated aggressively with antiepileptic drugs during the acute illness (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .). Most patients will not require long term AED therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/56/906/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall prognosis in patients with these disorders is highly variable, depending on the underlying tumor and its stage as well as the severity of the neurologic syndrome. Delay to diagnosis and treatment has been associated with a worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3372297\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic encephalomyelitis is characterized by involvement of several areas of the nervous system, including the temporal-limbic regions, brainstem, cerebellum, spinal cord, dorsal root ganglia, and autonomic nervous system. The distribution of disease and symptoms varies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limbic encephalitis (LE) is characterized by acute or subacute mood and behavioral changes, short-term memory problems, complex-partial seizures, and cognitive dysfunction. (See",
"      <a class=\"local\" href=\"#H3370754\">",
"       'Limbic encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent neoplasms associated with paraneoplastic LE are cancer of the lung (usually SCLC), seminoma and other testicular tumors, thymoma, breast cancer, and Hodgkin lymphoma, and the most frequently associated antibody is the anti-Hu antibody. (See",
"      <a class=\"local\" href=\"#H3370754\">",
"       'Limbic encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with anti-Hu encephalomyelitis often have multifocal neurologic involvement affecting temporal lobes, brainstem, cerebellum, dorsal roots,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autonomic nervous system. In many patients, symptoms begin with, and may remain restricted to, the dorsal root ganglia, causing a subacute sensory neuronopathy; other patients present with a more restricted brainstem or limbic encephalitis. (See",
"      <a class=\"local\" href=\"#H3373108\">",
"       'Anti-Hu encephalomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other intracellular antigens (Ma2, CRMP5, etc.) have been characterized. The distinctive clinical features of their associated syndromes are described. (See",
"      <a class=\"local\" href=\"#H3372425\">",
"       'Antibodies to intracellular antigens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmunity to synaptic proteins can also produce a limbic encephalitis. These syndromes are variably associated with cancer. Anti-NMDA receptor encephalomyelitis is the best studied of these to date. (See",
"      <a class=\"local\" href=\"#H3370782\">",
"       'Antibodies to synaptic proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paraneoplastic and autoimmune encephalitis need to be distinguished from viral encephalitis as well as other infectious, inflammatory, and vascular disorders affecting the brain. Metabolic and toxic encephalopathies should be excluded as well as metastatic spread of the underlying cancer to the brain or meninges. (See",
"      <a class=\"local\" href=\"#H5280997\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with this clinical presentation will have neuroimaging, EEG, lumbar puncture, and serologic testing for appropriate biomarkers (",
"      <a class=\"graphic graphic_algorithm graphicRef72802 \" href=\"UTD.htm?32/41/33438\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12091013\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An algorithmic approach to the diagnosis and treatment of paraneoplastic and autoimmune encephalitis is presented in the Figure (",
"      <a class=\"graphic graphic_algorithm graphicRef72802 \" href=\"UTD.htm?32/41/33438\">",
"       algorithm 1",
"      </a>",
"      ). Specific antineoplastic treatment may result in neurologic improvement. Immunosuppressive therapies may help if the tumor is also treated and in non-paraneoplastic syndromes. Because of the risk of permanent sequelae, use of immunosuppressive therapy should not await cancer diagnosis or antibody characterization in patients with the characteristic clinical and radiologic presentation in whom infection, especially herpes simplex encephalitis, has been ruled out. (See",
"      <a class=\"local\" href=\"#H2380193\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/1\">",
"      Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/2\">",
"      Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965; 88:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/3\">",
"      Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994; 44:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/4\">",
"      Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/5\">",
"      Graus F, Keime-Guibert F, Re&ntilde;e R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/6\">",
"      Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/7\">",
"      Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/8\">",
"      Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/9\">",
"      Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123 ( Pt 7):1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/10\">",
"      Lawn ND, Westmoreland BF, Kiely MJ, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/11\">",
"      Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011; 96:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/12\">",
"      Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/13\">",
"      Alamowitch S, Graus F, Uchuya M, et al. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120 ( Pt 6):923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/14\">",
"      Moragas M, Mart&iacute;nez-Y&eacute;lamos S, Maj&oacute;s C, et al. Rhombencephalitis: a series of 97 patients. Medicine (Baltimore) 2011; 90:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/15\">",
"      Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and \"optic neuritis\": paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/16\">",
"      Saiz A, Bruna J, Stourac P, et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 2009; 80:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/17\">",
"      Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/18\">",
"      Mut M, Schiff D, Dalmau J. Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. J Neurooncol 2005; 72:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/19\">",
"      Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999; 45:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/20\">",
"      Kinirons P, O'Dwyer JP, Connolly S, Hutchinson M. Paraneoplastic limbic encephalitis presenting as lingual epilepsia partialis continua. J Neurol 2006; 253:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/21\">",
"      Jacobs DA, Fung KM, Cook NM, et al. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci 2003; 213:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/22\">",
"      van Broekhoven F, de Graaf MT, Bromberg JE, et al. Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2010; 81:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/23\">",
"      Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/24\">",
"      Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/25\">",
"      Byrne T, Mason WP, Posner JB, Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997; 62:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/26\">",
"      Dalmau J, Gultekin SH, Voltz R, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 ( Pt 1):27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/27\">",
"      Waragai M, Chiba A, Uchibori A, et al. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry 2006; 77:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/28\">",
"      Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007; 68:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/29\">",
"      Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/30\">",
"      Blumenthal DT, Salzman KL, Digre KB, et al. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology 2006; 67:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/31\">",
"      Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/32\">",
"      Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/33\">",
"      Muehlschlegel S, Okun MS, Foote KD, et al. Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder. Mov Disord 2005; 20:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/34\">",
"      Werry C, G&ouml;tz F, Wurster U, et al. Paraneoplastic autoimmune encephalitis associated with CV2/CRMP-5 IgG antineuronal antibodies in a patient with thymoma. J Neurol 2009; 256:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/35\">",
"      Rickman OB, Parisi JE, Yu Z, et al. Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 2000; 75:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/36\">",
"      Wessig C, Klein R, Schneider MF, et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/37\">",
"      Sabater L, G&oacute;mez-Choco M, Saiz A, Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol 2005; 170:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/38\">",
"      Knudsen A, Bredholt G, Storstein A, et al. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol 2007; 149:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/39\">",
"      Okamoto S, Hirano T, Takahashi Y, et al. Paraneoplastic limbic encephalitis caused by ovarian teratoma with autoantibodies to glutamate receptor. Intern Med 2007; 46:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/40\">",
"      T&uuml;z&uuml;n E, Rossi JE, Karner SF, et al. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 2007; 186:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/41\">",
"      Harloff A, Hummel S, Kleinschmidt M, Rauer S. Anti-Ri antibodies and limbic encephalitis in a patient with carcinoid tumour of the lung. J Neurol 2005; 252:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/42\">",
"      Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/43\">",
"      Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/44\">",
"      Dalmau J, T&uuml;z&uuml;n E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/45\">",
"      Shimazaki H, Ando Y, Nakano I, Dalmau J. Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. J Neurol Neurosurg Psychiatry 2007; 78:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/46\">",
"      Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008; 70:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/47\">",
"      Seki M, Suzuki S, Iizuka T, et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008; 79:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/48\">",
"      Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/49\">",
"      Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr 2010; 22:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/50\">",
"      Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/51\">",
"      Zandi MS, Irani SR, Follows G, et al. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology 2009; 73:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/52\">",
"      Novillo-L&oacute;pez ME, Rossi JE, Dalmau J, Masjuan J. Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. Neurology 2008; 70:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/53\">",
"      Smith JH, Dhamija R, Moseley BD, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol 2011; 68:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/54\">",
"      Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010; 67:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/55\">",
"      Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/56\">",
"      Kawachi I, Saji E, Toyoshima Y, et al. Treatment responsive opsoclonus-ataxia associated with ovarian teratoma. J Neurol Neurosurg Psychiatry 2010; 81:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/57\">",
"      Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/58\">",
"      Sansing LH, T&uuml;z&uuml;n E, Ko MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007; 3:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/59\">",
"      Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009; 28:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/60\">",
"      Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009; 66:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/61\">",
"      Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/62\">",
"      Pr&uuml;ss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010; 75:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/63\">",
"      Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/64\">",
"      Lebas A, Husson B, Didelot A, et al. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J Child Neurol 2010; 25:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/65\">",
"      Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009; 66:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/66\">",
"      Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008; 71:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/67\">",
"      Gabilondo I, Saiz A, Gal&aacute;n L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011; 77:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/68\">",
"      Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/69\">",
"      Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010; 107:3799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/70\">",
"      Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 2011; 76:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/71\">",
"      Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/72\">",
"      Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/73\">",
"      Jacob S, Irani SR, Rajabally YA, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry 2008; 79:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/74\">",
"      Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/75\">",
"      Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010; 81:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/76\">",
"      Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/77\">",
"      Bataller L, Galiano R, Garc&iacute;a-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010; 74:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/78\">",
"      Graus F, Boronat A, Xifr&oacute; X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010; 74:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/79\">",
"      Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/80\">",
"      Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/81\">",
"      Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/82\">",
"      Cornelius JR, Pittock SJ, McKeon A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol 2011; 68:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/83\">",
"      Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011; 76:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/84\">",
"      Kr&ouml;ll-Seger J, Bien CG, Huppertz HJ. Non-paraneoplastic limbic encephalitis associated with antibodies to potassium channels leading to bilateral hippocampal sclerosis in a pre-pubertal girl. Epileptic Disord 2009; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/85\">",
"      Bien CG, Elger CE. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 2007; 10:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/86\">",
"      Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011; 82:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/87\">",
"      Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/88\">",
"      Clerinx K, Breban T, Schrooten M, et al. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy. Neurology 2011; 76:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/89\">",
"      Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 2011; 77:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/90\">",
"      Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/91\">",
"      Blanc F, Ben Abdelghani K, Schramm F, et al. Whipple limbic encephalitis. Arch Neurol 2011; 68:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/92\">",
"      Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/93\">",
"      Kaniecki R, Morris JC. Reversible paraneoplastic limbic encephalitis. Neurology 1993; 43:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/94\">",
"      T&uuml;z&uuml;n E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007; 13:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/56/906/abstract/95\">",
"      Darnell RB, Posner JB. A new cause of limbic encephalopathy. Brain 2005; 128:1745.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15759 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_906=[""].join("\n");
var outline_f0_56_906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3372297\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3369874\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3370740\">",
"      CLINICAL AND PATHOLOGICAL OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3370747\">",
"      Myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3370754\">",
"      Limbic encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3372592\">",
"      Brainstem encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3372409\">",
"      SPECIFIC ANTIBODY-RELATED SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3372425\">",
"      Antibodies to intracellular antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3373108\">",
"      - Anti-Hu encephalomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370761\">",
"      - Ma2-associated encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5281280\">",
"      - Anti-CRMP5 encephalomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12091957\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3370782\">",
"      Antibodies to synaptic proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370789\">",
"      - Anti-NMDA receptor encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370796\">",
"      - Encephalitis and LGI1 antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370803\">",
"      - Encephalitis and AMPA receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370810\">",
"      - Anti-GABA-B encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3370817\">",
"      - Anti-CASPR-2 associated encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4565291\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3372498\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280997\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12091013\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2380193\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3372297\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15759|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/41/33438\" title=\"algorithm 1\">",
"      Approach to paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15759|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/24/31110\" title=\"picture 1\">",
"      Reactivity of paraneoplastic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/48/40711\" title=\"picture 2\">",
"      Paraneoplastic brainstem encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/60/32717\" title=\"table 1\">",
"      Paraneoplastic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/59/8125\" title=\"table 2\">",
"      Treatment of paraneoplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_56_907="Complications of cirrhosis";
var content_f0_56_907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of cirrhosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Variceal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous bacterial peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatorenal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatopulmonary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_907=[""].join("\n");
var outline_f0_56_907=null;
var title_f0_56_908="Symptoms of cervical root lesions";
var content_f0_56_908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical signs and symptoms in typical solitary cervical root lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Root",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pain",
"      </td>",
"      <td class=\"subtitle1\">",
"       Numbness",
"      </td>",
"      <td class=\"subtitle1\">",
"       Weakness",
"      </td>",
"      <td class=\"subtitle1\">",
"       Reflex affected",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C5",
"      </td>",
"      <td>",
"       Neck, shoulder, scapula",
"      </td>",
"      <td>",
"       Lateral arm (in distribution of axillary nerve)",
"      </td>",
"      <td>",
"       Shoulder abduction, external rotation, elbow flexion, forearm supination",
"      </td>",
"      <td>",
"       Biceps, brachioradialis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C6",
"      </td>",
"      <td>",
"       Neck, shoulder, scapula, lateral arm, lateral forearm, lateral hand",
"      </td>",
"      <td>",
"       Lateral forearm, thumb and index finger",
"      </td>",
"      <td>",
"       Shoulder abduction, external rotation, elbow flexion, forearm supination and pronation",
"      </td>",
"      <td>",
"       Biceps, brachioradialis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C7",
"      </td>",
"      <td>",
"       Neck, shoulder, middle finger, hand",
"      </td>",
"      <td>",
"       Index and middle finger, palm",
"      </td>",
"      <td>",
"       Elbow and wrist extension (radial), forearm pronation, wrist flexion",
"      </td>",
"      <td>",
"       Triceps",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C8",
"      </td>",
"      <td>",
"       Neck, shoulder, medial forearm, fourth and fifth digits, medial hand",
"      </td>",
"      <td>",
"       Medial forearm, medial hand, fourth and fifth digits",
"      </td>",
"      <td>",
"       Finger extension, wrist extension (ulnar), distal finger flexion, extension, abduction and adduction, distal thumb flexion",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       Neck, medial arm and forearm",
"      </td>",
"      <td>",
"       Anterior arm and medial forearm",
"      </td>",
"      <td>",
"       Thumb abduction, distal thumb flexion, finger abduction and adduction",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_908=[""].join("\n");
var outline_f0_56_908=null;
var title_f0_56_909="Cl dependence of renin release";
var content_f0_56_909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chloride and renin release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 215px; height: 171px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dependence of the equivalent short circuit current (Isc, a measure of active NaCl transport) on the luminal concentrations of K+, Na+, and Cl- in the cortical thick ascending limb of the loop of Henle in the rabbit. The carrier has a very high affinity for Na+ and K+, reaching near maximum activity at concentrations under 10 meq/L; as a result, the luminal Cl- concentration is normally the rate- limiting step in NaCl entry into the cell. A similar process occurs in the medullary thick ascending limb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Greger, R, Velazquez, H, Kidney Int 1987; 31:590. Reprinted by permission from Kidney International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_56_909=[""].join("\n");
var outline_f0_56_909=null;
var title_f0_56_910="Contents: Dermatitis";
var content_f0_56_910=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Dermatitis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dermatitis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Atopic dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42631\">",
"           Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44457\">",
"           Management of severe refractory atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26551\">",
"           Role of allergy in atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10842\">",
"           Treatment of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Contact dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/3/7223\">",
"           Basic mechanisms and pathophysiology of allergic contact dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/42/11943\">",
"           Clinical features and diagnosis of allergic contact dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26104\">",
"           Contact dermatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/20/29001\">",
"           Irritant contact dermatitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/63/32758\">",
"           Management of allergic contact dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28150\">",
"           Patch testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20168\">",
"           Poison ivy (Toxicodendron) dermatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other types of eczematous dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/59/27576\">",
"           Acute palmoplantar eczema (dyshidrotic eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/14/2278\">",
"           Cradle cap and seborrheic dermatitis in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5336\">",
"           Dermatitis of the vulva",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3721\">",
"           Overview of dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/43/44727\">",
"           Prurigo nodularis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21961\">",
"           Seborrheic dermatitis in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29288\">",
"           Stasis dermatitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E80E14ED96-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f0_56_910=[""].join("\n");
var outline_f0_56_910=null;
var title_f0_56_911="Contents: Men's health issues";
var content_f0_56_911=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Men's health issues",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Men's health issues",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Androgen deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36562\">",
"           Patient information: Androgen replacement in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18578\">",
"           Patient information: Low testosterone in men (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast enlargement in men",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41713\">",
"           Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/30/44513\">",
"           Patient information: When men develop breasts (gynecomastia) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Contraception",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22563\">",
"           Patient information: Barrier methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9157\">",
"           Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/56/14211\">",
"           Patient information: Choosing birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12738\">",
"           Patient information: Emergency contraception (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24068\">",
"           Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/17/18707\">",
"           Patient information: Hormonal birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/32/22021\">",
"           Patient information: Hormonal methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/17/37138\">",
"           Patient information: Intrauterine devices (IUD) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/22/1378\">",
"           Patient information: Long-acting methods of birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4355\">",
"           Patient information: Long-term methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7620\">",
"           Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/51/23346\">",
"           Patient information: Sterilization for women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29730\">",
"           Patient information: Vasectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36242\">",
"           Patient information: Vasectomy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hair loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24817\">",
"           Patient information: Alopecia areata (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/18/7458\">",
"           Patient information: Hair loss in men and women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17282\">",
"           Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prostate cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3315\">",
"           Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11202\">",
"           Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/3/2099\">",
"           Patient information: Prostate cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38770\">",
"           Patient information: Prostate cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/27/32176\">",
"           Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40565\">",
"           Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/41/42643\">",
"           Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prostate disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28467\">",
"           Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15698\">",
"           Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/11/29873\">",
"           Patient information: Prostatitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35987\">",
"           Patient information: Urinary incontinence in men (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Quitting smoking",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19670\">",
"           Patient information: Quitting smoking (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18146\">",
"           Patient information: Quitting smoking (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rape",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1509\">",
"           Patient information: Care after sexual assault (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scrotum and testicles",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/30/18914\">",
"           Patient information: Epididymitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17873\">",
"           Patient information: Hydrocele (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17217\">",
"           Patient information: Varicocele (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexual and reproductive issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40401\">",
"           Patient information: Balanitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22180\">",
"           Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6547\">",
"           Patient information: Infertility in couples (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40610\">",
"           Patient information: Infertility in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/40/34433\">",
"           Patient information: Priapism (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/386\">",
"           Patient information: Sex problems in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29205\">",
"           Patient information: Sexual problems in men (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32851\">",
"           Patient information: Treatment of male infertility (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29730\">",
"           Patient information: Vasectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36242\">",
"           Patient information: Vasectomy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/14/24802\">",
"           Patient information: Chlamydia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23362\">",
"           Patient information: Chlamydia and gonorrhea (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36916\">",
"           Patient information: Genital herpes (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/44/1730\">",
"           Patient information: Gonorrhea (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27843\">",
"           Patient information: Pubic lice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1940\">",
"           Patient information: Screening for sexually transmitted diseases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10195\">",
"           Patient information: Syphilis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1986\">",
"           Patient information: Testing for HIV (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Testicular cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24645\">",
"           Patient information: Testicular cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31538\">",
"           Patient information: Testicular cancer (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-51D8896479-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f0_56_911=[""].join("\n");
var outline_f0_56_911=null;
